Dr. Halene is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Park St.
New Haven, CT 06520Phone+1 203-200-4363
Education & Training
- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
- Eberhard Karls University Faculty of MedicineClass of 1993
Certifications & Licensure
- CT State Medical License 2006 - 2025
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 709 citationsEndotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.George Goshua, Alexander B Pine, Matthew L Meizlish, C-Hong Chang, Hanming Zhang
The Lancet. Haematology. 2020-08-01 - 283 citationsViral replication in human macrophages enhances an inflammatory cascade and interferon driven chronic COVID-19 in humanized mice.Esen Sefik, Rihao Qu, Eleanna Kaffe, Jun Zhao, Haris Mirza
Biorxiv. 2021-09-27 - 5 citationsMission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies.Jane C Figueiredo, Fred R Hirsch, Lawrence H Kushi, Wendy N Nembhard, James M Crawford
Open Forum Infectious Diseases. 2022-06-01
Journal Articles
- SRSF2 Mutations Drive Oncogenesis by Activating a Global Program of Aberrant Alternative Splicing in Hematopoietic CellsRadovan Vasic, Stephanie Halene, Nature
Abstracts/Posters
- Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 InhibitionStephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceStephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant DiseaseStephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- New Yale Study Shows Potential Target for Treating Blood CancersMarch 31st, 2022
- Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid OrgansOctober 20th, 2021
- Student Research Day Celebrates Students and MentorsJune 1st, 2021
- Join now to see all
Grant Support
- Role Of C/Ebpepsilon In Myeloid DifferentiationNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: